Payers

Latest News


This week The American Journal of Managed Care launched its new Managed Markets News Network, featuring the top stories in managed care and interviews with industry experts.

The pharmaceutical industry has learnt its lesson from the pushback that Gilead faced over the price of its hepatitis C drug, Sovaldi. The lack of a price discussion prior to the introduction of the regimen washed-out the excitement over a "cure" for the disease.

With a focus on improving quality while maintaining the cost of care, providers and payers are evaluating various payment models that could improve patient outcomes using evidence-based treatment at lower costs to the healthcare system.

As patents on some of the most lucrative medicines began to expire, many companies shifted money to rare-disease drugs, knowing that those medicines cost less to develop and will face limited competition.

The Patient Access Network or PAN Foundation formed more than 10 years ago, partially in response to the Medicare Part D benefit. It helps patients meet cost-sharing requirements across dozens of diseases, including 25 in oncology; Evidence-Based Oncology, a publication of The American Journal of Managed Care, invited PAN Foundation President and CEO Dan Klein to discuss its role in immuno-oncology.

The goals of the new CMS Oncology Care Model align very nicely with what payers want, according to Ira M. Klein, MD, MBA, FACP, national medical director, clinical thought leadership, office of the chief medical officer, Aetna.

The panelists discuss the evidence that is weighed when determining whether or not to include a particular therapy on their regimens.

Among publications in the managed care field, The American Journal of Managed Care (AJMC) is likely the leader, according to Mitch DeKoven, principal of health economics and outcomes research at IMS Health.